Celgene — Proxy Contest (May 2018)
28 slides from Celgene's proxy contest presentation, May 18, 2018
Slide 1: Business Update and Overview of Independent Board Leadership
Business Update and Overview of Independent Board Leadership May 2018 C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE
Slide 2: Forward Looking Statements and Adjusted Financial Information
Forward Looking Statements and Adjusted Financial Information 2 This presentation contains forward - looking statements, which are generally statements that are not historical facts . Forward - looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estima
Slide 3: Executive Summary
Executive Summary 3 • We are accelerating diversification by advancing medicines to transform the treatment of diseases, within hematology, oncology, inflammation and immunology • We have a robust R&D engine delivering first - and best - in - class programs through our centers of excellence and part
Slide 4: Our Mission and Vision
Our Mission and Vision 4 Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune - inflammatory, and other unmet medical needs
Slide 5: Deploying a Strategy to Grow Through 2020 and Beyond
Deploying a Strategy to Grow Through 2020 and Beyond Execute Delivering on 2020 Accelerate Positioning to Grow Beyond 2020 Expand Creating Sustainable Growth 5
Slide 6: 2017 Performance Highlights
2017 Performance Highlights 6 Financial Highlights • Net product sales: $12,973 million, an increase of 16% • Total revenue: $13,003 million, an increase of 16% • GAAP Net income: $2,940 million, an increase of 47% • Diluted GAAP EPS: $3.64, an increase of 46% • Adjusted net income*: $6,016 million,
Slide 7: Long-Term Value Creation for Shareholders
Long - Term Value Creation for Shareholders 7 Five - Year Cumulative Total Shareholder Return Assessing five - year cumulative total shareholder return, a $ 100 investment in the Company’s Common Stock on December 31 , 2012 would have grown 166 % to approximately $ 266 on December 31 , 2017 , as dep
Slide 8: Strong Volume-Driven Growth Expected in 2018
Strong Volume - Driven Growth Expected in 2018 8 % 18 EPS Y/Y growth* ~$9.5B Diluted EPS* ~$1.9B + ~$1.0B *Adjusted financial measure which includes the impact of our acquisition of Juno Therapeutics Inc., which is expected to be d ilu tive to adjusted EPS in 2018 by approximately $0.50. EPS Y/Y gro
Slide 9: Accelerating Diversification by Advancing Medicines to Transform Treatment of Diseases
Multiple Myeloma Accelerating Diversification by Advancing Medicines to Transform the Treatment of Diseases 9 Market Opportunity $27B Incidence 60K HEMATOLOGY & ONCOLOGY Non - Hodgkin Lymphoma Market Opportunity $17B Incidence 90K Myeloid Diseases Market Opportunity $5B Incidence 65K Psoriasis / Pso
Slide 10: R&D Engine: Building a Pipeline of Next-Generation Growth Drivers
R&D Engine Building a Pipeline of Next - Generation Growth Drivers 10 Centers of Excellence Partner Network Epigenetics Immuno - Oncology Inflammation & Immunology Protein Homeostasis Neuroscience & Imaging Innovation Engine Advancing 8 New Programs into the Clinic ▪ Next - Gen CELMoD ® ▪ Ph I for M
Slide 11: Delivering Industry-Leading Growth Through 2020
Delivering Industry - Leading Growth Through 2020… Late - stage Pipeline with Potential to Add Over $16B in Incremental Peak Revenue Through 2030 11 …And Positioned to Grow Beyond 2020 Expect to Launch Ten Potential Blockbusters Adj. Diluted EPS Total Revenue ~19% CAGR 14.5% CAGR Note: CAGR calculat
Slide 12: Enhancing Our Board and Management Team
Enhancing Our Board and Management Team to Fully Capitalize on the Next Innovation Cycle 12 • Following the appointment of two new independent directors in 2018, and four since 2015, we continue to evaluate opportunities to enhance our Board’s diversity and independence as part of ongoing efforts to
Slide 13: Board Structured to Provide Independent Oversight and Diversity
Board Structured to Provide Independent Oversight and Diversity 13 Active Independent Oversight Practices 1 Source : Spencer Stuart Board Index 2016 . x Independent Lead Director role with responsibilities in line with industry norms x Regular Board assessment of optimal leadership structure x Indep
Slide 14: Board Composition Provides Diversity and Balance of Skill Sets
Board Composition Provides Diversity, Balance of Skill Sets, and Other Experience Relevant to Our Business 14 Celgene’s Board has implemented practices that enhance independent oversight of management The Nominating Committee assesses the needs of the Board and the Company to recruit directors who h
Slide 15: Independent Lead Director Provides Active Oversight
Independent Lead Director Provides Active Oversight 15 Michael D. Casey, Independent Lead Director • Mr . Casey’s breadth of experience in management, operations, and corporate governance led independent directors to appoint him to this Board leadership role • Mr . Casey has held several prominent r
Slide 16: Responsive to Shareholder Feedback
Responsive to Shareholder Feedback 16 We maintain a robust investor outreach program that provides ongoing feedback concerning our compensation programs and other governance matters Key Highlights and Actions Taken • We proactively reach out to shareholders representing more than 50 % of the outstan
Slide 17: Effective Board Leadership Structure Best Serves Shareholder Interests
Effective Board Leadership Structure Best Serves Shareholder Interests 17 The Board recommends that shareholders vote against the proposal to require an independent Board Chairman, as it will impede the Board’s flexibility in determining the Company’s leadership structure that best serves the Compan
Slide 18: Executive Compensation Aligns Pay and Performance
Executive Compensation Aligns Pay and Performance 18 Celgene’s Board has implemented practices that enhance independent oversight of management As supported by 95% Say on Pay vote for our 2017 executive compensation for NEOs A significant percentage of compensation awards to Celgene’s NEOs is variab
Slide 19: Recognized for Commitment to Our Patients and the Broader Community
Recognized for Commitment to Our Patients and the Broader Community 19 Underlying our Company’s culture is a strong belief in corporate responsibility that is predicated on our purpose, values, an d behaviors, which are the foundation of our approach to ethical and responsible business activities 1
Slide 20: Use of Non-GAAP Financial Measures and Reconciliation Tables
Use of Non - GAAP Financial Measures and Reconciliation Tables C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE
Slide 21: Use of Non-GAAP Financial Measures
Use of Non - GAAP Financial Measures 21 Use of Non - GAAP Financial Measures In addition to financial information prepared in accordance with U . S . GAAP, this document also contains certain non - GAAP financial measures based on management’s view of performance including : Adjusted research and de
Slide 22: Use of Non-GAAP Financial Measures
Use of Non - GAAP Financial Measures 22 Share - based Compensation Expense : We exclude share - based compensation from our adjusted financial results because share - based compensation expense, which is non - cash, fluctuates from period to period based on factors that are not within our control, s
Slide 23: Use of Non-GAAP Financial Measures
Use of Non - GAAP Financial Measures 23 Certain Other Items : We exclude certain other significant items that may occur occasionally and are not normal, recurring, cash operating expenses from our adjusted financial results . Such items are evaluated on an individual basis based on both the quantita
Slide 24: Use of Non-GAAP Financial Measures: Long-Term Targets
Use of Non - GAAP Financial Measures 24 Long - Term Targets A reconciliation of long - term adjusted financial targets to the most comparable GAAP measures cannot be provided because we are unable to forecast with reasonable certainty many of the items necessary to calculate such comparable GAAP mea
Slide 25: Reconciliation Tables
Reconciliation Tables Dy & ws or spor ad sot $ ets ba sy oneal ano (cs ee Femipy- aes [ay 8 ome sean face, oe) 3) ow sana gg inda pa ‘mor me a 2 8 eam te pa "a aa) 90 > rE o aan Cnn og rug Rip qe ys SoD ie Yan sae an pan cs so 6 sr apo poe pep ° aden indameomapawemee sods eure po Hes “conser pened B
Slide 26: Reconciliation Tables
Reconciliation Tables 26 Explanation of adjustments: (1) Exclude share - based compensation expense totaling $162 for the three - month period ended December 31, 2017 and $155 for the three - month period ended December 31, 2016. Exclude share - based compensation expense totaling $644 for the twelv
Slide 27: ‘rpite fuao nop ete ate ies ssa ues apna tes oD
ar ‘rpite fuao nop ete ate ies ssa ues apna tes oD TH aT sospogy st phan os srs poy -wrtsanos page it nse pi ie eos avv0- wroozuos pares se sana ne i 2 pany esa: pnbie Dv wo exumuipran awadvong uo © ‘espe qr a me pS ‘somo oo ow wo series ete quay 3 ar » be pane ty o cy semadsnssrporsgupeoominnns peg
Slide 28: Business Update and Overview of Independent Board Leadership
May 2018 C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE Business Update and Overview of Independent Board Leadership